Download
s00259-020-05120-2.pdf 461,18KB
WeightNameValue
1000 Titel
  • The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
1000 Autor/in
  1. Marina, Boccardi |
  2. Dodich, Alessandra |
  3. Albanese, Emiliano |
  4. Gayet-Ageron, Angèle |
  5. Festari, Cristina |
  6. Ashton, Nicholas J. |
  7. Bischof, Gérard N. |
  8. Chiotis, Konstantinos |
  9. Leuzy, Antoine |
  10. Wolters, Emma E. |
  11. Walter, Martin A. |
  12. Rabinovici, Gil D. |
  13. Carrillo, Maria |
  14. Drzezga, Alexander |
  15. Hansson, Oskar |
  16. Nordberg, Agneta |
  17. Ossenkoppele, Rik |
  18. Villemagne, Victor L. |
  19. Winblad, Bengt |
  20. Frisoni, Giovanni B. |
  21. Garibotto, Valentina |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-10
1000 Erschienen in
1000 Quellenangabe
  • 48(7):2070-2085
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-020-05120-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175304/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!The 2017 Alzheimer's disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1-2), clinical validity (Phases 3-4), and clinical utility (Phase 5) through primary and secondary Aims. This framework allows to map knowledge gaps and research priorities, accelerating the route towards clinical implementation. Within an initiative aimed to assess the development of biomarkers of tau pathology, we revised this methodology consistently with progress in AD research.!##!Methods!#!We critically appraised the adequacy of the 2017 Biomarker Roadmap within current diagnostic frameworks, discussed updates at a workshop convening the Alzheimer's Association and 8 leading AD biomarker research groups, and detailed the methods to allow consistent assessment of aims achievement for tau and other AD diagnostic biomarkers.!##!Results!#!The 2020 update applies to all AD diagnostic biomarkers. In Phases 2-3, we admitted a greater variety of study designs (e.g., cross-sectional in addition to longitudinal) and reference standards (e.g., biomarker confirmation in addition to clinical progression) based on construct (in addition to criterion) validity. We structured a systematic data extraction to enable transparent and formal evidence assessment procedures. Finally, we have clarified issues that need to be addressed to generate data eligible to evidence-to-decision procedures.!##!Discussion!#!This revision allows for more versatile and precise assessment of existing evidence, keeps up with theoretical developments, and helps clinical researchers in producing evidence suitable for evidence-to-decision procedures. Compliance with this methodology is essential to implement AD biomarkers efficiently in clinical research and diagnostics.
1000 Sacherschließung
lokal Dementia
lokal Disease Progression [MeSH]
lokal Reference Standards [MeSH]
lokal Humans [MeSH]
lokal Neurology – Dementia
lokal Cognitive Dysfunction [MeSH]
lokal Amyloid beta-Peptides [MeSH]
lokal Validation methodology
lokal Cross-Sectional Studies [MeSH]
lokal Alzheimer Disease/diagnosis [MeSH]
lokal Biomarker
lokal Alzheimer’s disease
lokal Original Article
lokal MCI
lokal tau Proteins [MeSH]
lokal Biomarkers [MeSH]
lokal Mild cognitive impairment
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-6744-8246|https://frl.publisso.de/adhoc/uri/RG9kaWNoLCBBbGVzc2FuZHJh|https://frl.publisso.de/adhoc/uri/QWxiYW5lc2UsIEVtaWxpYW5v|https://frl.publisso.de/adhoc/uri/R2F5ZXQtQWdlcm9uLCBBbmfDqGxl|https://frl.publisso.de/adhoc/uri/RmVzdGFyaSwgQ3Jpc3RpbmE=|https://frl.publisso.de/adhoc/uri/QXNodG9uLCBOaWNob2xhcyBKLg==|https://frl.publisso.de/adhoc/uri/QmlzY2hvZiwgR8OpcmFyZCBOLg==|https://frl.publisso.de/adhoc/uri/Q2hpb3RpcywgS29uc3RhbnRpbm9z|https://frl.publisso.de/adhoc/uri/TGV1enksIEFudG9pbmU=|https://frl.publisso.de/adhoc/uri/V29sdGVycywgRW1tYSBFLg==|https://frl.publisso.de/adhoc/uri/V2FsdGVyLCBNYXJ0aW4gQS4=|https://frl.publisso.de/adhoc/uri/UmFiaW5vdmljaSwgR2lsIEQu|https://frl.publisso.de/adhoc/uri/Q2FycmlsbG8sIE1hcmlh|https://frl.publisso.de/adhoc/uri/RHJ6ZXpnYSwgQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/SGFuc3NvbiwgT3NrYXI=|https://frl.publisso.de/adhoc/uri/Tm9yZGJlcmcsIEFnbmV0YQ==|https://frl.publisso.de/adhoc/uri/T3NzZW5rb3BwZWxlLCBSaWs=|https://frl.publisso.de/adhoc/uri/VmlsbGVtYWduZSwgVmljdG9yIEwu|https://frl.publisso.de/adhoc/uri/V2luYmxhZCwgQmVuZ3Q=|https://frl.publisso.de/adhoc/uri/RnJpc29uaSwgR2lvdmFubmkgQi4=|https://frl.publisso.de/adhoc/uri/R2FyaWJvdHRvLCBWYWxlbnRpbmE=
1000 Hinweis
  • DeepGreen-ID: fb8191ad845a45f8aec35c8afec9e444 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451563.rdf
1000 Erstellt am 2023-05-11T13:58:49.121+0200
1000 Erstellt von 322
1000 beschreibt frl:6451563
1000 Zuletzt bearbeitet Tue Oct 24 08:29:38 CEST 2023
1000 Objekt bearb. Tue Oct 24 08:29:38 CEST 2023
1000 Vgl. frl:6451563
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451563 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source